Alterations in Antioxidant Status and Biochemical Indices Following Administration of Dihydroartemisinin-Piperaquine Phosphate (P-ALAXIN® )

Olayinka, Ebenezer Tunde

doi:10.9790/3008-0544353

Cited by 3 publications

(4 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the choice of malaria partner-drugs was predominantly SP and different 4-aminoquinolines, namely lumefantrine, amodiaquine, and piperaquine. To date, artemisinin derivatives enjoy a favourable cardiovascular profile as reported in normal individuals with malaria, in experimental situations, and in usual doses [10,16,21,25] . However even such reports have acknowledged electrical abnormalities, including QRS morphological alterations, and blood pressure changes, though with unclear clinical implications [16,21,25] .…”

Section: Discussionmentioning

confidence: 94%

“…Lumefantrine, amodiaquine and piperaquine as partner-drugs appear to have a safe cardiovascular profile [11,16,20] . However, recent publications are calling for caution with these drug classes, as changes in antioxidant status and adverse renal changes have been observed [25] . The authors noted that piperaquine is a bisquinoline and structurally related to chloroquine.…”

Section: Discussionmentioning

confidence: 99%

“…The authors noted that piperaquine is a bisquinoline and structurally related to chloroquine. Thus it was expected to exhibit electrophysiological effects on the heart [25] . We also reiterate that caution be exercised on the use of lumefantrine and piperaquine combinations in cardiac patients because of their close structural resemblance to halofantrine and other 4-aminoquinolines.…”

Section: Discussionmentioning

confidence: 99%

“…Thus further studies are required especially on the use of 4-amino-quinololines such as lumefantrine and piperaquine in heart failure patients. Drug reviews have previously noted that amodiaquine as a single agent was shown to increase heart rate and resulted in toxic effects on some liver and renal function tests [20,25] . The authors cautioned that although certain medications which did not have a direct effect on the heart; but altered hepatic and renal profiles may indirectly affect the heart [20,25] by affecting drug metabolism of heart failure drugs or malaria drugs [25] .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Pattern of antimalaria treatment and risk factors for torsades de pointes in admitted heart failure patients in Lagos-Nigeria

Ajuluchukwu

Anyika

Boyle

2014

JHA

View full text Add to dashboard Cite

Background: In a malaria-holoendemic region, concurrent malaria complicating heart failure (HF) occurs; with higher morbidity and increased adverse drug-drug interactions. Aim: To characterise malaria treatment and risk factors of cardio-toxicity among HF patients. Objectives: To characterise the use of anti-malaria agents (AMA), compare risk factors of torsades de pointes (TdP) amongst AMA-users and non-users, and to assess length of hospital stay. Methods: Admitted HF patients were retrospectively studied, and grouped on the basis of malaria treatment. TdP risk factors- advanced age, bradycardia, hypokalemia, and QTc prolongation were compared in the two groups. Results: The 160 HF patients (mean ejection fraction 39.6% ± 12.6%, mean age 54.9 ± 14.6 years) included 82 males (51.3%), with predominant non-ischemic HF. Malaria treatment occurred in 32.5% (52), though diagnosis was presumptive in 48 (92.3%). All (100%) malaria prescriptions were artemisinin-based, but monotherapeutic in 6 (11.4%). Partner-drugs included sulphadoxine-pyrimethamine (SP) 26 (50%), and lumefantrine 7 (13.5%). TdP risk-factors of age 65 years, prolonged QTc, hypokalemia, and bradycardia occurred in 43 (26.9%), 63 (39.4%), 48 (30%), and 8 (5.0%) respectively. Group 1 (AMA treated) and group 2 patients were comparable on all mean values of risk factors. Nevertheless, affected proportions were significantly different for hypokalemia (X2 = 6.1), QTc prolongation (48.1% versus 35.2%, p < .05), and older age (38.5% versus, 21.3%, p < .05%). Conclusion: Though all HF patients similarly demonstrated risks of TdP, univariate analysis indicates a significantly higher proportion in malaria-treated patients; supporting further therapeutic caution in this patient subset.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Pattern of antimalaria treatment and risk factors for torsades de pointes in admitted heart failure patients in Lagos-Nigeria

Ajuluchukwu

Anyika

Boyle

2014

JHA

View full text Add to dashboard Cite

show abstract

Unsweetened Natural Cocoa Powder Has the Potential to Attenuate High Dose Artemether‐Lumefantrine‐Induced Hepatotoxicity in Non‐Malarious Guinea Pigs

Asiedu-Gyekye

Kukuia

Seidu³

et al. 2016

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. This study investigated the elemental composition of unsweetened natural cocoa powder (UNCP), its effect on nitric oxide, and its hepatoprotective potential during simultaneous administration with high-dose artemether/lumefantrine (A/L). Method. Macro- and microelements in UNCP were analyzed with EDXRF spectroscopy. Thirty (30) male guinea-pigs were then divided into five groups. For groups 3 (low-dose), 4 (medium-dose), and 5 (high-dose), the animals received oral UNCP prophylactically for 14 days. Group 1 received distilled water (14 days) and group 2 A/L for the last 3 days (days 12 to 14). After euthanisation, biochemical and histopathological examinations were carried out in all groups. Results. Phytochemical analysis of UNCP showed the presence of saponins, flavonoids, tannins, and cardiac glycosides. Thirty-eight (38) macro- and microelements were found. UNCP produced significant decreases in ALT, ALP, GGT, and AST levels. A significant increase in total protein levels was observed during A/L+UNCP administration in comparison to 75 mg/kg A/L group. Histopathological examinations buttressed the protective effects of cocoa administration. UNCP administration increased nitric oxide levels 149.71% (P < 0.05) compared to controls. Conclusion. UNCP increases nitric oxide levels and has hepatoprotective potential during A/L administration. A high level of copper was observed which may be detrimental during high daily consumptions of UNCP.

show abstract

Effect of Artemisinin-Based Combination Therapy on some Selected Liver Function Indices of Pregnant Wistar Albino Rats

2013

J App Pharm Sci

View full text Add to dashboard Cite

In the risk assessment of the effect of administration of artemisinin-based combination therapy on some selected liver function indices of pregnant wistar albino rats. Fifteen (15) pregnant wistar albino rats were divided into three groups and were allowed to acclimatize to laboratory condition for seven (7) days. Rats in group A served as the control and were administered with normal saline throughout the experimental period of seven ( 7) days, while rats in group B and C were administered intra-peritoneally with 3 and 6mg/kg body weight of artemisininbased combination therapy respectively throughout the experimental period. Twenty four (24) hours after the last administration, the pregnant wistar albino rats were sacrificed. Blood was obtained by cardiac puncture for analysis of serum ALP, AST, ALT and bilirubin using standard methods and enzyme kits. The result showed that the drug at both 3and 6mg/kg body weight produced a significant (P<0.05) dosage increase in serum AST, ALT and ALP. The ratio of AST: ALT and AST: ALP showed a significant (P<0.05) increase. Similar pattern was also displayed by serum bilirubin concentration. These results are clear manifestations that artemisinin-based combination therapy might pose hepatic injury, hepatobilliary toxicity or complete hepatic damage in pregnant wistar albino rats. Thus, it is suggested that special precaution needs to be exercised on the usage of artemetherlumefantrine in pregnancy.

show abstract

Alterations in Antioxidant Status and Biochemical Indices Following Administration of Dihydroartemisinin-Piperaquine Phosphate (P-ALAXIN® )

Abstract: Dihydroartemisinin-piperaquine phosphate (P-ALAXIN ® ) is a fixed-dose artemisinin-based combination therapy (ACT).

Cited by 3 publications

References 61 publications

Pattern of antimalaria treatment and risk factors for torsades de pointes in admitted heart failure patients in Lagos-Nigeria

Pattern of antimalaria treatment and risk factors for torsades de pointes in admitted heart failure patients in Lagos-Nigeria

Unsweetened Natural Cocoa Powder Has the Potential to Attenuate High Dose Artemether‐Lumefantrine‐Induced Hepatotoxicity in Non‐Malarious Guinea Pigs

Effect of Artemisinin-Based Combination Therapy on some Selected Liver Function Indices of Pregnant Wistar Albino Rats

Contact Info

Product

Resources

About